Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 23, 2017
Pharmacy Choice - Pharmaceutical News - Findings from Erasmus University Medical Center in Psoriasis Reported (The cost-effectiveness of blue-light therapy in the treatment of... - July 23, 2017

Pharmacy News Article

 5/19/17 - Findings from Erasmus University Medical Center in Psoriasis Reported (The cost-effectiveness of blue-light therapy in the treatment of...

Findings from Erasmus University Medical Center in Psoriasis Reported (The cost-effectiveness of blue-light therapy in the treatment of mild-to-moderate psoriasis)

By a News Reporter-Staff News Editor at Health & Medicine Week Data detailed on Skin Diseases and Conditions - Psoriasis have been presented. According to news reporting out of Rotterdam, Netherlands, by NewsRx editors, research stated, "To investigate the cost-effectiveness of blue-light therapy versus a two-compound formulation (TCF) (Dovobet gel [calcipotriol and betamethasone]) in mild-to-moderate psoriasis. A Markov model was applied to describe the course of disease among Dutch patients with a Psoriasis Area and Severity Index (PASI) score less than or equal to 10 over a 52-week time horizon."

Our news journalists obtained a quote from the research from Erasmus University Medical Center, "Patients received either 12-week blue-light therapy or two 4-week treatments with TCF. experiencing no PASI reduction after either therapy, were assumed to receive 12-week ultraviolet B phototherapy. There was no significant difference in PASI reduction between two interventions (71 vs 72%). However, blue-light therapy was associated with a cost savings of EU?248."

According to the news editors, the research concluded: "Treatment of mild-to-moderate chronic plaque psoriasis using blue-light therapy may be more cost-effective than TCF."

For more information on this research see: The cost-effectiveness of blue-light therapy in the treatment of mild-to-moderate psoriasis. Journal of Comparative Effectiveness Research, 2017;(): (see also Skin Diseases and Conditions - Psoriasis).

Our news journalists report that additional information may be obtained by contacting A. Ansaripour, Institute for Medical Technology Assessment, Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, Netherlands. Additional authors for this research include H.B. Thio, R. Maessen and W.K Redekop.

Keywords for this news article include: Europe, Therapy, Rotterdam, Psoriasis, Netherlands, Dermatology, Papulosquamous Skin Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC



(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jul 24: What's New? New Treatments for Type 2 Diabetes
Jul 26: Management of Schizophrenia & Acute Agitation
Jul 27: On the Move: A Comprehensive Review of Osteoarthritis, Gout & Rheumatoid Arthritis
Jul 31: Obesity Management: Overview of Pharmacotherapy
Aug 01: Treatment of Depression and Anxiety in Older Adults
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415